Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis

Raia, V.; Maluri, L.; Ciacci, C.; Ricciardelli, I.; Vacca, L.; Auricchio, S.; Cimmino, M.; Cavaliere, M.; Nardone, M.; Cesaro, A.; Malcolm, J.; Quaratino, S.; Londei, M.
September 2005
Thorax;Sep2005, Vol. 60 Issue 9, p773
Academic Journal
Background: Cystic fibrosis (CF) airways are characterised by chronic inflammation, increased interleukin (IL)-8 secretion, and neutrophil activation which are considered the principal factors of morbidity and mortality in CF patients. Optimising management of this chronic inflammatory response is therefore a key issue of basic and clinical CF research. Several reports have addressed ways to manage CF airways inflammation, and an attractive therapeutic strategy may be the inhibition of the p38-mitogen activated protein kinase (p38-MAP-k) pathway. Methods: A new ex vivo model was used to study the mucosal inflammatory response to environmental airways stimuli. Nasal biopsy tissues from CF patients and controls were cultured ex vivo for 20 minutes, 4 hours, and 24 hours in the presence of lipopolysaccharide (LPS) from Pseudomonas aeruginosa (PA) with and without the p38-MAP-k inhibitor SB203580. Quantitative mRNA assessment, immunohistochemistry, and Western blots were used to detect the expression and modulation of inflammatory markers. Results: PA-LPS challenge induced a time dependent mucosal inflammation indicated by rapid epithelial activation, IL-8 release, COX-2 upregulation, and neutrophil migration to the upper mucosal layers. Some of these LPS induced changes (IL-8 release and neutrophil migration) were specific to CF tissues. SB203580 significantly controlled all LPS induced mucosal changes in CF tissues. conclusion: These findings provide a rationale and proof of principle for the potential use of p38-MAP-k inhibitors to control inflammation in patients with CF.


Related Articles

  • Altered sialyl- and fucosyl-linkage on mucins in cystic fibrosis patients promotes formation of the sialyl-Lewis X determinant on salivary MUC-5B and MUC-7. Shori, D. K.; Genter, T.; Hansen, J.; Koch, C.; Wyatt, H.; Kariyawasam, H. H.; Knight, R. A.; Hodson, M. E.; Kalogeridis, A.; Tsanakas, I. // Pflugers Archiv European Journal of Physiology;Nov2001 Supplement 1, Vol. 443, pS55 

    Destruction of the lungs as a consequence of recurrent infections with microorganisms such as Pseudomonas aeruginosa remains the underlying cause of most morbidity and mortality in cystic fibrosis (CF). We have hypothesized that changes in the glycosylation of key tracheal mucins such as MUC5B...

  • Molecular studies of CFTR interacting proteins. Wang, Shusheng; Li, Min // Pflugers Archiv European Journal of Physiology;Nov2001 Supplement 1, Vol. 443, pS62 

    Transport via the cystic fibrosis transmembrane conductance regulator (CFTR) is activated by its interactions with cytoplasmic cofactors, such as cAMP-activated protein kinases. CFTR activity is also known to couple to other ion channels and transporters. Although the genetic cause of human...

  • Dual regulation of cardiac Na+-K+ pumps and CFTR Cl– channels by protein kinases A and C. Erlenkamp, Simone; Glitsch, Helfried G.; Kockskämper, Jens // Pflugers Archiv European Journal of Physiology;May2002, Vol. 444 Issue 1/2, p251 

    Regulation of Na+-K+ pump current (Ip) and cystic fibrosis transmembrane conductance regulator (CFTR) Cl– current (ICFTR) by protein kinases A and C (PKA and PKC) was compared under identical experimental conditions by simultaneous measurement of the two currents in guinea-pig ventricular...

  • Regulation of the CFTR channel by phosphorylation. Dahan, David; Evagelidis, Alexandra; Hanrahan, John W.; Hinkson, Deborah A. R.; Jia, Yanlin; Luo, Jiexin; Zhu, Tang // Pflugers Archiv European Journal of Physiology;Nov2001 Supplement 1, Vol. 443, pS92 

    Cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels are regulated tightly by protein kinases and phosphatases. The regulatory domain of CFTR has about 20 potential sites for phosphorylation by protein kinases A (PKA) and C (PKC). The reason for this large number of sites...

  • Myeloperoxidase Promoter Polymorphism -463G Is Associated With More Severe Clinical Expression of Cystic Fibrosis Pulmonary Disease. Reynolds, Wanda F.; Sermet-Gaudelus, Isabelle; Gausson, Val�rie; Feuillet, Marie-No�lle; Bonnefont, Jean-Paul; Lenoir, G�rard; Descamps-Latscha, B�atrice; Witko-Sarsat, V�ronique // Mediators of Inflammation;4/1/2006, Vol. 2006 Issue 2, p1 

    The severity of cystic fibrosis (CF) pulmonary disease is not directly related to CFTR genotype but depends upon several parameters, including neutrophil-dominated inflammation. Identification of agents modulating inflammation constitutes a relevant goal. Myeloperoxidase (MPO) is involved in...

  • Inhibition of NFκB by the natural product Withaferin A in cellular models of Cystic Fibrosis inflammation. Maitra, Rangan; Porter, Melissa A.; Shan Huang; Gilmour, Brian P. // Journal of Inflammation;2009, Vol. 6, p1 

    Cystic Fibrosis (CF) is one of the most common autosomal genetic disorders in humans. This disease is caused by mutations within a single gene, coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The phenotypic hallmark of CF is chronic lung infection and...

  • CFTR and lysozyme secretion in human airway epithelial cells. Duszyk, M. // Pflugers Archiv European Journal of Physiology;Nov2001 Supplement 1, Vol. 443, pS45 

    Lysozyme is secreted in large quantities in human airways (10–20 mg/day), where it helps to defend against bacterial and fungal infection. Lysozyme expression is restricted to the serous cells of the submucosal glands, which also express high levels of cystic fibrosis transmembrane...

  • Correlation of forced oscillation technique in preschool children with cystic fibrosis with pulmonary inflammation. Brennan, S.; Hall, G. L.; Horak, F.; Moeller, A.; Pitrez, P. M. C.; Franzmann, A.; Turner, S.; De Klerk, N.; Franklin, P.; Winfield, K. R.; Balding, E.; Stick, S. M.; Sly, P. D. // Thorax;Feb2005, Vol. 60 Issue 2, p159 

    Background: Lung disease in cystic fibrosis (CF) is established in early childhood with recurrent bacterial infections and inflammation. Using spirometry, the effect of this early lung damage cannot be measured until a child is 6 years of age when some irreversible lung damage may already have...

  • Chronic sinusitis in cystic fibrosis. Mackay, I. S.; Djazaeri, B. // Journal of the Royal Society of Medicine (Supplement);Jan1994, Vol. 87 Issue 21, p17 

    The article focuses on the prevalence of chronic sinusitis in patients with cystic fibrosis. The causes of chronic sinusitis in patients with cystic fibrosis are explored. The diagnosis and treatment of chronic sinusitis is also tackled. Also included is the surgical treatment and complications...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics